|
KMID : 1148920080420000091
|
|
Nuclear Medicine and Molecular Imaging
2008 Volume.42 No. 0 p.91 ~ p.100
|
|
|
Clinical Application of 18F-FDG PET in Ovarian Cancer
|
|
Oh So-Won
Kim Seok-Ki
|
|
|
Abstract
|
|
|
Ovarian cancer is often fatal since it is difficult to diagnose early and recurrence is quite frequent despite successful implementation of cytoreductive surgery and chemotherapy, thus exact diagnosis and early detection of recurrence are crucial to patient management. For pre-treatment staging, FDG PET could be helpful in a limited patient group possessing high risks of ovarian cancer. Besides, FDG PET could be recommended to patients with a high suspicion of recurrence i.e. rise of CA-125, especially in cases of conventional diagnostic imaging modalities presenting no evidence of disease
because FDG PET provides critical information for treatment planning such as recurrence site or pattern. In order to expand the use of FDG PET to general population at staging or routine surveillance of ovarian cancer, more investigation is eeded.
The usefulness of FDG PET in evaluating treatment response and prognosis of ovarian cancer has not yet been
determined, but it has been reported that FDG PET could evaluate treatment response early and show a close relationship with overall survival. PET/CT has been actively adopted in management of ovarian cancer. Not only in detecting tumor recurrence and evaluating treatment response but also in pre-treatment staging, FDG PET/CT is expected to play a role due to available anatomical information. (Nucl Med Mol Imaging 2008;42(suppl 1):91-100)
|
|
|
KEYWORD
|
|
|
ovarian cancer, FDG PET
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|